Nasdaq
$15.62▲ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.58BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 2d agoAfter-hours26.10.23 05:104Ownership#●●●
Dyne Therapeutics, Inc.
Executive Douglas Kerr of Dyne Therapeutics reported a change in beneficial ownership of securities on October 20, 2026. This filing is a Form 4 statement detailing the insider's updated stock holdings.…more
$15.62+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:154Ownership
Dyne Therapeutics, Inc.
Dyne Therapeutics insider Brian S. Posner filed a Form 4 on October 6, 2026, reporting a change in beneficial ownership of company securities as of October 2, 2026. This filing serves as a routine disclosure of changes in stock holdings by company management.…more
$15.62+0.06%vs prev closeView filingShare - 9.29After-hours26.09.30 05:108-KKey event
Dyne Therapeutics, Inc.
Dyne Therapeutics announced additional 12-month clinical data from the Phase 1/2 ACHIEVE trial of its DM1 candidate, z-basivarsen (DYNE-101). The pooled dose group analysis demonstrated sustained functional improvements across multiple measures, including myotonia, muscle strength, and patient-reported outcomes, compared to placebo and matched natural history cohorts. The company expects topline data from the registrational expansion cohort in Q1 2027, aiming for a U.S. Accelerated Approval BLA submission in Q3 2027.…more
$15.62+0.06%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:05#●●●
Dyne Therapeutics Grants Equity Awards to New Hires
Dyne Therapeutics has granted equity awards to 16 newly hired employees in accordance with Nasdaq listing rules. This is a standard recruitment incentive and does not reflect immediate changes to the company's financial performance or business outlook.…more
$15.62+0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29After-hours26.09.30 05:05
●●●●●●●● ●●●●● ●●●●●●
Dyne Therapeutics announced that its Phase 1/2 trial for z-basivarsen in DM1 patients showed functional improvements over 12 months compared to natural history cohorts. The company plans to use these results to support a potential U.S. Accelerated Approval submission in Q3 2027.…more
$15.62+0.06%vs prev close - 9.17After-hours26.09.18 05:05
●●●●●●●● ●●●●● ●●●●●●
Dyne Therapeutics has granted stock options and restricted stock units totaling 366,500 shares to 14 newly hired employees. These inducement awards are part of standard recruitment efforts under Nasdaq listing rules and have no immediate material impact on the company's financials.…more
$15.62+0.06%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report